Fig. 2: YTHDC1 suppresses the malignant progression of bladder cancer cells.

a–e T24 and 5637 cells were transfected with the indicated siRNAs for 48 h. Cells were collected for western blot analysis (a), a CCK-8 assay (b), a colony formation assay (c), a transwell assay (d), and a wound healing assay (e). The data are presented as the mean ± SEM of three replicates. *P < 0.05; **P < 0.01; ***P < 0.001. f and g T24 and 5637 cells were transfected with the indicated plasmids for 48 h. The cells were harvested for western blot analysis (f) and a CCK-8 assay (g). The data are presented as the mean ± SEM of three replicates. ***P < 0.001. h–k T24 and 5637 cells were transfected with the indicated constructs for 48 h. Cells were collected for western blot analysis (h), a CCK-8 assay (i), a wound healing assay (j), and a transwell assay (k). The data are presented as the mean ± SEM of three replicates. ***P < 0.001. l–m T24 cells were infected with the indicated shRNAs for 72 h. After puromycin selection, cells were collected for western blot analysis (l), a colony formation assay (m and n), and a nude mouse xenograft assay (o–s). For the colony formation assay and Ki-67 IHC staining, data are presented as the mean ± SEM of three replicates. For the xenograft assay, data are presented as the mean ± SEM of six replicates. **P < 0.01; ***P < 0.001.